MML Investors Services LLC lifted its position in Repligen Co. (NASDAQ:RGEN – Get Rating) by 14.8% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 11,061 shares of the biotechnology company’s stock after buying an additional 1,429 shares during the period. MML Investors Services LLC’s holdings in Repligen were worth $2,070,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD raised its stake in shares of Repligen by 46.5% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 5,531,521 shares of the biotechnology company’s stock worth $898,319,000 after buying an additional 1,755,417 shares in the last quarter. Sands Capital Management LLC acquired a new position in Repligen during the third quarter valued at $306,666,000. Artisan Partners Limited Partnership raised its position in Repligen by 640.9% during the second quarter. Artisan Partners Limited Partnership now owns 1,176,883 shares of the biotechnology company’s stock valued at $191,126,000 after buying an additional 1,018,034 shares during the period. William Blair Investment Management LLC acquired a new position in Repligen during the second quarter valued at $119,053,000. Finally, Pendal Group Ltd purchased a new position in Repligen in the third quarter valued at about $83,613,000. Institutional investors own 91.00% of the company’s stock.
Analyst Ratings Changes
RGEN has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Repligen in a research report on Tuesday, December 13th. They set a “hold” rating and a $180.00 price objective for the company. SVB Leerink cut their price target on Repligen from $230.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, January 6th. Royal Bank of Canada began coverage on Repligen in a report on Tuesday, December 6th. They issued a “sector perform” rating and a $190.00 price target for the company. Craig Hallum dropped their target price on Repligen from $251.00 to $220.00 in a report on Thursday, February 23rd. Finally, William Blair restated an “outperform” rating on shares of Repligen in a research report on Wednesday, November 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $216.86.
Repligen Stock Down 0.1 %
Repligen (NASDAQ:RGEN – Get Rating) last released its quarterly earnings results on Wednesday, February 22nd. The biotechnology company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.10. The firm had revenue of $186.80 million for the quarter, compared to the consensus estimate of $184.41 million. Repligen had a return on equity of 10.31% and a net margin of 23.20%. The company’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter last year, the business posted $0.81 EPS. As a group, equities research analysts expect that Repligen Co. will post 2.65 earnings per share for the current year.
About Repligen
Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs.
Featured Stories
- Get a free copy of the StockNews.com research report on Repligen (RGEN)
- Reserve Your Spot With These Hotels The Analysts Support
- Cruise Line Stocks Still Have Some Choppy Waters to Navigate
- Four Vegan Food Stocks Performing Beyond the Norm
- Ocean Interest Electrifies Fisker Stock
- Is Freshpet Ready For A Fresh Rally?
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Get Rating).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
